Helio Health and Fulgent Genetics to Present New Data on HelioLiver in Late-Breaking Presentation at The Liver Meeting® 2021
Helio Health and Fulgent Genetics announced a late-breaking poster presentation on HelioLiver, a blood test for detecting hepatocellular carcinoma (HCC), at The Liver Meeting® 2021, scheduled for November 12-15, 2021. The test uses cell-free DNA methylation patterns and protein markers to improve early cancer detection. The presentation will feature David J. Taggart, PhD, and aims to highlight significant advancements in liver cancer screening. Helio Health focuses on AI-driven cancer detection, while Fulgent Genetics specializes in genetic testing innovations.
- None.
- None.
IRVINE, Calif. and TEMPLE CITY, Calif., Nov. 1, 2021 /PRNewswire/ -- Helio Health ("Helio"), an AI-driven healthcare company developing blood-based early cancer detection tests, and Fulgent Genetics, Inc. (NASDAQ: FLGT) ("Fulgent"), a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, today announced its upcoming late-breaking poster presentation on the performance of HelioLiver, a multi-analyte blood test that utilizes both cell-free DNA (cfDNA) methylation patterns and protein tumor markers for the detection of hepatocellular carcinoma (HCC), at The Liver Meeting® 2021. The annual meeting is hosted by the American Association for the Study of Liver Diseases (AASLD) and will be held virtually November 12-15, 2021.
Details of the poster presentation are as follows:
Poster Title: A Multi-Analyte Blood Test for Accurate and Early Detection of Hepatocellular Carcinoma
Publication Number: LP44
Session Title: Late-breaking Abstract Posters
Presenter: David J. Taggart, PhD, NRCC(CC) – Laboratory Director and Vice President of Laboratory Operations and Regulatory Affairs, Helio Health Inc.
The full abstract can be found here. The poster presentation will be available for viewing by the attendees of The Liver Meeting® throughout the entire meeting.
About Helio Health
Helio Health is an AI-driven healthcare company focused on commercializing early cancer detection tests from a simple blood draw. The company's mission is to simplify cancer screening so lives can be saved by detecting cancer earlier. With Helio's AI-driven technology, both physicians and their patients gain powerful insights from accurate, accessible, and convenient blood tests.
Building on a robust research and development program, and with access to thousands of patient samples, the company is currently in clinical trials in the US and China with its lead liver cancer detection test. Helio's development program is focused on liver, colon, breast and lung cancer.
Helio Health is headquartered in Irvine, CA, with R&D, GMP and CLIA facilities in Irvine, CA and West Lafayette, IN, Guangzhou and Beijing.
About Fulgent Genetics
Fulgent Genetics is a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health. Fulgent's proprietary technology platform has created a broad, flexible test menu and the ability to continually expand and improve its proprietary genetic reference library while maintaining accessible pricing, high accuracy, and competitive turnaround times. Combining next generation sequencing with its technology platform, Fulgent performs full-gene sequencing with deletion/duplication analysis in an array of panels that can be tailored to meet specific customer needs. A cornerstone of our business is our ability to provide expansive options and flexibility for all clients' unique testing needs through a comprehensive technology offering including cloud computing, pipeline services, record management, web portal services, clinical workflow, sequencing as a service and automated lab services.
About Helio Health and Fulgent Genetics Partnership
In a strategic partnership announced in August of 2021, Helio Health and Fulgent Genetics plan to commercialize and co-brand HelioLiver, a cell-free DNA (cfDNA) methylation blood test that incorporates protein markers and demographics for the detection of hepatocellular carcinoma (HCC) – or liver cancer. HelioLiver is currently undergoing clinical trials in the U.S. and China. Fulgent will be responsible for laboratory operations, supply chain operations, and marketing and sales leveraging its operational excellence and significant market reach, initially focused in the U.S. and Canada. Helio will provide intellectual property and continued support across research and development, publication development, market access and sales, as well as reimbursement operations. Fulgent and Helio will also collaborate on the development of additional liquid biopsy tests for different types of cancer in the future.
View original content to download multimedia:https://www.prnewswire.com/news-releases/helio-health-and-fulgent-genetics-to-present-new-data-on-helioliver-in-late-breaking-presentation-at-the-liver-meeting-2021-301413267.html
SOURCE Helio Health and Fulgent Genetics, Inc.
FAQ
What is HelioLiver and why is it important for FLGT?
When and where will the HelioLiver poster presentation take place?
Who is presenting the research on HelioLiver at The Liver Meeting?
What technology does Helio Health use for early cancer detection?
What is the partnership between Helio Health and Fulgent Genetics?
